Yendou, a Berlin-based startup specializing in clinical operations automation, has secured $1.3M (approximately €1.20M) in a pre-seed funding round. The investment was led by b2venture, with participation from Heartfelt, Infinite Fund, and pharmaceutical industry angels, including Lindus Health co-founder Meri Beckwith.
The funding aims to boost operational efficiency in clinical trials, particularly in oncology, expediting drug development processes. Yendou addresses the significant bottleneck in the clinical site selection process, which accounts for a third of clinical trial timelines. The startup’s platform focuses on clinic recruitment for cancer clinical trials, filling a crucial gap in the industry’s approach.
Advertisement
Empowering Pharmaceutical Companies with Data
Yendou empowers pharmaceutical companies with data to efficiently select the best clinics for their trials. “Choosing the right clinic is crucial for patient recruitment success,” says Yendou CEO and co-founder, Zina Sarif. The platform serves as the first CRM tool in research and development, helping clinical operations teams accelerate site selection to activation timelines for oncology clinical trials globally.
A Salesforce for R&D Teams in Life Sciences
Co-founder Sarif describes Yendou as “Salesforce for R&D teams in life sciences,” offering a unique value proposition by providing a curated pool of qualified clinical leads. The platform aims to eliminate repetitive work and consolidate information, accelerating the pace of clinical trials delivery to clinics.
Gaining Traction and Entering Closed Beta
Since its launch in March 2023, Yendou has gained traction with over 1,200 clinicians across 46 countries. Responding to demand, the platform enters a closed beta for pharmaceutical and biotech firms, facilitating site selection and onboarding for Phase II and Phase III oncology trials.
About the Lead Investor
b2venture, founded in 2000, is one of Europe’s most experienced venture capital firms. With offices in Berlin, Zurich, Munich, and Luxembourg, b2venture focuses on early-stage investments and supports unique entrepreneurs and groundbreaking ideas. Deploying over €100M annually across Europe, b2venture has built a robust investor community and backed companies including 1KOMMA5°, DeepL, Facebook, Raisin, Foodspring, ORCAM, SumUp, Volocopter, and XING.
With this pre-seed funding, Yendou is well-positioned to revolutionize the efficiency of clinical trials, particularly in oncology, offering pharmaceutical companies the tools to navigate the complexities of clinic selection and patient recruitment.
